Esophageal Cancer

P=N/A, N=90, Recruiting, Sunshine Coast University Hospital | Not yet recruiting --> Recruiting

The study reveals that microplastics, as emerging pollutants, can enhance tumor cell proliferation and harm normal esophageal epithelium. These results suggest that NPs exhibit dual toxicological effects on tumor cells and normal esophageal epithelial cell models.

P=N/A, N=2000, Recruiting, Flinders University of South Australia | Not yet recruiting --> Recruiting

P1, N=56, Active, not recruiting, Legend Biotech USA Inc | Recruiting --> Active, not recruiting

In esophageal tumors, adjuvant nivolumab is used. Among HER2-positive patients, adding pembrolizumab to trastuzumab and chemotherapy - in PDL1 CPS ≥1 cases - has become a new standard. A special mention must be made of MSI-H tumors, in which immunotherapy is highly effective, and adjuvant chemotherapy is not recommended according to current guidelines.

Western blot results showed that the expression of β-catenin in the OE-AK094457 group was significantly lower than that in the other two groups, indicating that lncRNA AK094457 can affect the malignant biological function of oesophageal cancer cells through the Wnt pathway (p < 0.001). Long non-coding RNA AK094457 can inhibit certain functions of oesophageal cancer cells, such as proliferation, migration and invasion, by activating the Wnt pathway.

Moreover, as one of the model CRGs, the tumor-suppressive role of SULT1B1 in ESCC was experimentally verified in vitro. These results provide novel insights into enhancing the prognosis of ESCC and formulating treatment strategies.

The validated IBS model provides high-precision prediction of postoperative LNM risk in ESCC. It offers a novel framework ("tumor antigen burden-lymphangiogenesis-immune microenvironment") for improving patient risk stratification, guiding adjuvant therapy decisions (including immunotherapy response prediction), and optimizing resource allocation, thereby potentially impacting ESCC management paradigms.

P2, N=48, Recruiting, The First Affiliated Hospital with Nanjing Medical University

Patients were randomized 1:1 to receive zolbetuximab plus chemotherapy or placebo plus chemotherapy (mFOLFOX6 [modified folinic acid, 5-fluorouracil, and oxaliplatin] or CAPOX [capecitabine and oxaliplatin]). Zolbetuximab plus chemotherapy demonstrated favorable PFS and OS versus placebo plus chemotherapy in the Korean subgroup, with numerically greater efficacy compared with the overall pooled population. This may be potentially attributable to low rates of zolbetuximab discontinuation and toxicity management.

Furthermore, a potential MIR4435-2HG/hsa-miR-125a-5p/NPM1 ceRNA axis was identified. Collectively, these findings indicate that NPM1 contributes to ESCA progression via metabolic modulation and ceRNA regulation, supporting its utility as a prognostic biomarker and therapeutic target.

P1, N=260, Not yet recruiting, IDEAYA Biosciences